New targets for antithrombotic drugs

American Journal of Cardiovascular Drugs

Volumn 2, Issue 4, 2002, Pages 227-235

  Thiagarajan, Perumal ^a,b  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b MICHAEL E DEBAKEY VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ARGATROBAN; AURINTRICARBOXYLIC ACID; BERAPROST; BLOOD CLOTTING FACTOR 10A; BLOOD CLOTTING FACTOR 10A INHIBITOR; CALCIUM ION; CLOPIDOGREL; ECHISTATIN; EPTIFIBATIDE; FIBRIN; FIBRINOGEN; FIBRINOGEN RECEPTOR; FIBRINOGEN RECEPTOR ANTAGONIST; FRADAFIBAN; GLYCOPROTEIN IB; HEPARIN; ILOPROST; LAMIFIBAN; LOW MOLECULAR WEIGHT HEPARIN; PROSTAGLANDIN; PROSTAGLANDIN E1; THROMBIN; THROMBIN INHIBITOR; TICLOPIDINE; UNINDEXED DRUG; VON WILLEBRAND FACTOR; XEMILOFIBAN;

ARTERY THROMBOSIS; ARTICLE; ATHEROSCLEROSIS; BLEEDING; BLOOD CLOTTING; BLOOD FLOW; BLOOD VESSEL INJURY; CALCIUM CELL LEVEL; CATALYSIS; CELL SHAPE; CLINICAL TRIAL; COMPLEX FORMATION; CONFORMATIONAL TRANSITION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CRYSTAL STRUCTURE; DRUG COST; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG TARGETING; DRUG TOLERABILITY; HEMOSTASIS; HUMAN; HYPOTENSION; INDUSTRIALIZATION; MORBIDITY; MORTALITY; NONHUMAN; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS; RECEPTOR DOWN REGULATION; RISK BENEFIT ANALYSIS; SIGNAL TRANSDUCTION; THROMBOCYTE ACTIVATION; THROMBOCYTE ADHESION; THROMBOCYTOPENIA; THROMBOSIS; VEIN THROMBOSIS; VENOUS STASIS;

EID: 0036383723     PISSN: 11753277     EISSN: None     Source Type: Journal    
DOI: 10.2165/00129784-200202040-00002     Document Type: Article

References (62)

1. Davie EW, Fujikawa K, Kisiel W. The coagulation cascade: initiation, maintenance, and regulation. Biochemistry 1991; 30: 10363-70
2. Broze Jr GJ. Tissue factor pathway inhibitor and the revised theory of coagulation. Annu Rev Med 1995; 46: 103-12
3. Edgington TS, Dickinson CD, Ruf W. The Structural basis of function of the TF. VIIa complex in the cellular initiation ot coagulation. Thromb Haemost 1997; 78: 401-5
4. Esmon CT. Regulation of blood coagulation. Biochim Biophys Acta 2000; 1477: 349-60
5. Andrews RK, Shen Y, Gardiner EE, et al. The glycoprotein Ib-IX-V complex in platelet adhesion and signaling. Thromb Haemost 1999; 82: 357-64
6. McGhie AI, McNatt J, Ezov N. et al. Abolition of cyclic flow variations in stenosed, endothelium-injured coronary arteries in nonhuman primates with a peptide fragment (VCL) derived from human plasma von Willebrand factor-glycoprotein Ib binding domain. Circulation 1994: 90: 2976-81
7. Matsuno H, Kozawa O, Niwa M, et al. Inhibition of von Willebrand factor binding to platelet GP Ib by a fractionated aurintricarboxylic acid prevents restenosis after vascular injury in hamster carotid artery. Circulation 1997; 96: 1299-304
8. Phillips MD, Moake JL, Nolasco L, et al. Aurin tricarboxylic acid: a novel inhibitor of the association of von Willebrand factor and platelets. Blood 1988; 72: 1898-903
9. Randomized trial of ridogrel, a combined thromboxane A2 synthase inhibitor and thromboxane A2/prostaglandin endoperoxide receptor antagonist, versus aspirin as adjunct to thrombolysis in patients with acute myocardial infarction. The Ridogrel Versus Aspirin Patency Trial (RAPT). Circulation 1997; 89: 588-95
10. Willis AL, Smith DL. Therapeutic impact of eicosanoids in atherosclerotic disease. Eicosanoids 1989; 2: 69
11. Ueno Y, Koike H, Nakamura Y, et al. Effects of beraprost sodium, a prostacyclin analogue, on diabetic neuropathy in streptozotocin-induced diabetic rats. Jpn J Pharmacol 1996; 70: 177-82
12. Hatori N, Takeshima S, Aoki T, et al. Effectiveness of prostaglandin E1 on pulmonary hypertension and right cardiac function induced by single-lung ventilation and hypoventilation. Ann Thorac Cardiovasc Surg 2000; 6: 236-41
13. Barnard EA, Simon J. An elusive receptor is finally caught: P2Y12, an important drug target in platelets. Trends Pharmacol Sci 2000; 22: 388-91
14. Gachet C. ADP receptors of platelets and their inhibition. Thromb Haemost 2001: 86: 222-32
15. Nandanan E, Jang SY, Moro S, et al. Synthesis, biological activity, and molecular modeling of ribose-modified deoxyadenosine bisphosphate analogues as P2Y(1) receptor ligands. J Med Chem 2000: 43: 829-42
16. Coller BS. Anti-GPIIb/IIIa drugs: current strategies and future directions. Thromb Haemost 2001; 86: 427-43
17. Blankenship JC, Tasissa G, O'Shea JC, et al. Effect of glycoprotein IIb/IIIa receptor inhibition on angiographic complications during percutaneous coronary intervention in the ESPRIT trial. J Am Coll Cardiol 2001; 38: 653-8
18. McLane MA, Vijay-Kumar S, Marcinkiewicz C, et al. Importance of the structure of the RGD-containing loop in the disintegrins echistatin and eristostatin for recognition of alpha IIb beta 3 and alpha v beta 3 integrins. FEBS Lett 1996; 391: 139-43
19. Topol EJ, Moliterno DJ, Herrmann HC, et al. Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization. N Engl J Med 2001; 344: 1988-94
20. Rydel TJ, Tulinsky A, Bode W, et al. Refined structure of the hirudin-thrombin complex. J Mol Biol 1991; 221: 583-601
21. Krishnan R, Zhang E, Hakansson K, et al. Highly selective mechanism-based thrombin inhibitors: structures of thrombin and trypsin inhibited with rigid peptidyl aldehydes. Biochemistry 1998; 37: 12094-103
22. Becker DL, Fredenburgh JC, Stafford AR, et al. Molecular basis for the resistance of fibrin-bound thrombin to inactivation by heparin/serpin complexes. Adv Exp Med Biol 1997; 425: 55-66
23. Chesebro JH. Direct thrombin inhibition superior to heparin during and after thrombolysis: dose, duration, and drug. Circulation 1997; 96: 2118-20
24. Greinacher A, Lubenow N. Recombinant hirudin in clinical practice: focus on lepirudin. Circulation 2001; 103: 1479-84
25. Bates SM, Weitz JI. The mechanism of action of thrombin inhibitors. J Invasive Cardiol 2000; 12: F27-32
26. Fenton II JW. Leeches to hirulogs and other thrombin-directed antithrombotics. Hematol Oncol Clin North Am 1992; 6: 1121-9
27. Scatena R. Bivalirudin: a new generation antithrombotic drug. Expert Opin Investig Drugs 2000; 9: 1119-27
28. McKeage K, Plosker GL. Argatroban. Drugs 2001; 61 (4): 515-22
29. Vermeer F, Vahanian A, Fels PW, et al. Argatroban and alteplase in patients with acute myocardial infarction: the ARGAMI Study. J Thromb Thrombolysis 2000; 10: 233-40
30. Eriksson H, Eriksson UG, Frison L, et al. Pharmacokinetics and pharmacodynamics of melagatran, a novel synthetic LMW thrombin inhibitor, in patients with acute DVT. Thromb Haemost 1999; 81: 358-63
31. Eriksson BI, Arfwidsson AC, Frison L, et al. A dose-ranging study of the oral direct thrombin inhibitor, ximelagatran, and its subcutaneous form, melagatran, compared with dalteparin in the prophylaxis of thromboembolism after hip or knee replacement: METHRO I. MElagatran for THRombin inhibition in Orthopaedic surgery. Thromb Haemost 2002; 87: 231-7
32. Linder R. Oldgren J, Egberg N, et al. The effect of a low molecular mass thrombin inhibitor, inogatran, and heparin on thrombin generation and fibrin turnover in patients with unstable coronary artery disease. Eur Heart J 1999: 20: 506-18
33. Yamashita T, Yamamoto J, Sasaki Y, et al. The antithrombotic effect of low molecular weight synthetic thrombin inhibitors, argatroban and PPACK, on He-Ne laser-induced thrombosis in rat mesenteric microvessels. Thromb Res 1993; 69: 93-100
34. Bracht F, Schror K. Isolation and functional characterization of DNA-derived aptamers that act as thrombin inhibitors in human platelets and coagulation assays. Agents Actions 1995; 45: 3 15-22
35. Brass LF. Thrombin receptor antagonists: a work in progress. Coron Artery Dis 1997; 8: 49-58
36. Reilly TM, Knabb RM, Hassell SM, et al. Effect of thrombin inhibitors on platelet functions: comparative analysis of DuP 7 14 and hirudin. Blood Coagul Fibrinolysis 1992; 3: 513-7
37. Church FC, Phillips JE, Woods JL. Chimeric antithrombin peptide. Characterization of an Arg-Gly-Asp (RGD)- and hirudin carboxyl terminus-containing synthetic peptides. J Biol Chem 1991; 266: 11975-9
38. Choay J. Structure and activity of heparin and its fragments: an overview. Semin Thromb Hemost 1989; 15: 359-64
39. Wilde MI, Markham A. Danaparoid: a review of its pharmacology and clinical use in the management of heparin-induced thrombocytopenia. Drugs 1997; 54: 903-24
40. Alving BM, Krishnamurti C. Recognition and management of heparin-induced thrombocytopenia (HIT) and thrombosis. Semin Thromb Hemost 1997; 23: 569-74
41. Sadler JE. Thrombomodulin structure and function. Thromb Haemost 1997; 78: 392-5
42. Gomi K, Zushi M, Honda G, et al. Antithrombotic effect of recombinant human thrombomodulin on thrombin-induced thromboembolism in mice. Blood 1990; 75: 1396-9
43. Dang OD, Vindigni A, Di Cera E. An allosteric switch controls the procoagulant and anticoagulant activities of thrombin. Proc Natl Acad Sci U S A 1995; 92: 5977-81
44. Gibbs CS, Coutre SE, Tsiang M, et al. Conversion of thrombin into an anticoagulant by protein engineering. Nature 1995; 378: 413-6
45. Leung LL, Gibbs CS. Modulation of thrombin's procoagulant and anticoagulant properties. Thromb Haemost 1997; 78: 577-80
46. Berg DT, Wiley MR, Grinnell BW. Enhanced protein C activation and inhibition of fibrinogen cleavage by a thrombin modulator. Science 1996: 273: 1389-91
47. Nicolini FA, Lee P, Malycky JL, et al. Selective inhibition of factor Xa during thrombolytic therapy markedly improves coronary artery patency in a canine model of coronary thrombosis. Blood Coagul Fibrinolysis 1996; 7: 39-48
48. Petitou M, Duchaussoy P, Jaurand G, et al. Synthesis and pharmacological properties of a close analogue of an antithrombotic pentasaccharide (SR 90107A/-ORG 31540). J Med Chem 1997: 40: 1600-7
49. Turpie AG, Gallus AS, Hoek JA. A synthetic pentasaccharide for the prevention of deep-vein thrombosis after total hip replacement. N Engl J Med 2001; 344: 619-25
50. Murayama N, Tanaka M, Kunitada S, et al. Tolerability, pharmacokinetics, and pharmacodynamics of DX-9065a, a new synthetic potent anticoagulant and specific factor Xa inhibitor, in healthy male volunteers. Clin Pharmacol Ther 1999; 66: 258-64
51. Wong PC, Crain EJ, Knabb RM. Nonpeptide factor Xa inhibitors II. Antithrombotic evaluation in a rabbit model of electrically induced carotid artery thrombosis. J Pharmacol Exp Ther 2000; 295: 212-8
52. Mao SS, Huang J, Welebob C, et al. Identification and characterization of variants of tick anticoagulant peptide with increased inhibitory potency toward human factor Xa. Biochemistry 1995; 34: 5098-103
53. Schaffer LW, Davidson JT, Vlasuk GP, et al. Selective factor Xa inhibition by recombinant antistasin prevents vascular graft thrombosis in baboons. Arterioscler Thromb 1992; 12: 879-85
54. Cappello M, Vlasuk GP, Bergum PW, et al. Ancylostoma caninum anticoagulant peptide: a hookworm-derived inhibitor of human coaguiationfactor Xa. Proc Natl Acad Sci U S A 1996; 93: 2149-54
55. Duggan BM, Dyson HJ, Wright PE. Inherent flexibility in a potent inhibitor of blood coagulation, recombinant nematode anticoagulant protein c2. Eur J Biochem 1999; 265: 539-48
56. Lee A, Agnelli G, Buller H. et al. Dose-response study of recombinant factor VIIa/tissue factor inhibitor recombinant nematode anticoagulant protein c2 in prevention of postoperative venous thromboembolism in patients undergoing total knee replacement. Circulation 2001; 104: 74-8
57. Broze Jr GJ. Tissue factor pathway inhibitor. Thromb Haemost 1995 Jul; 74 (1): 90-3
58. Presta L, Sims P, Meng YG, et al. Generation of a humanized, high affinity anti-tissue factor antibody for use as a novel antithrombotic therapeutic. Thromb Haemost 2001; 85: 379-89
59. Himber J, Refino CJ, Burcklen L, et al. Inhibition of arterial thrombosis by a soluble tissue factor mutant and active site-blocked factors IXa and Xa in the guinea pig. Thromb Haemost 2001; 85: 475-81
60. Subramaniam M, Frenette PS, Saffaripour S, et al. Defects in hemostasis in P-selectin-deficient mice. Blood 1996; 87: 1238-42
61. Angelillo-Scherrer A, de Frutos P, Aparicio C, et al. Deficiency or inhibition of Gas6 causes platelet dysfunction and protects mice against thrombosis. Nat Med 2001; 7: 215-21
62. Kawai T, Andrews D, Colvin RB, et al. Thromboembolic complications after treatment with monoclonal antibody against CD40 ligand [letter]. Nat Med 2000; 6: 114